"Roflumilast Cream Superior to Vehicle in Treatment of Plaque Psoriasis"
Roflumilast cream was superior to vehicle cream in attaining Investigator’s Global Assessment status of clear or almost clear at 6 weeks in patients with plaque psoriasis, according to a study in The New England Journal of Medicine.
“The topical PDE-4 inhibitor roflumilast, a once-daily cream consisting of roflumilast in a high-water-content moisturizing cream base vehicle containing the cosmetic solvent ethoxydiglycol, is being investigated for the treatment of plaque psoriasis,” Mark G. Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai, New York, and colleagues wrote. “In this phase 2b trial, we evaluated the efficacy and safety of two dose levels of roflumilast cream, administered daily over a period of 12 weeks, for the treatment of plaque psoriasis.”
Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
Jul 15, 2020 View All Press Releases